Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.

Tech Transfer regular column feature image

CEO Stephen Isaacs describes Aduro Biotech Inc.'s recently signed immuno-oncology collaboration with Stanford University as an effort to join wheels to a car, "so hopefully we can go on a very nice journey together."

The agreement, announced Jan. 17, will combine Aduro's personalized live, attenuated double-deleted Listeria (LADD) immunotherapy platform with an algorithm developed by Stanford associate professor of medicine Hanlee Ji to identify...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business